Clinical trial · Observational
Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)
Genomic Profile and Tumor Immune Attack in Paraneoplastic Neurological Syndromes (PNS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system. PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role. Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology. To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis. The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS. In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Immune System and Related Disorders | — | UNRESOLVED | — |
| Neurologic Disorder | — | UNRESOLVED | — |
| Paraneoplastic Syndromes | — | UNRESOLVED | — |
| Tumor Genetics | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Cancer patients with Paraneoplastic neurological syndromes
- description
- Cancer patients with Paraneoplastic neurological syndromes presenting various autoimmune anomalies: * Anti-Hu also known as anti-Neuron specific cell Nuclear Antibodies (anti-ANNA1) (350 patients), uncommon form of brain inflammation associated with an underlying cancer * anti-Yo (130 patients), antibody associated with paraneoplastic cerebellar degeneration * anti-Ma2 (50 patients), antibody associated with paraneoplastic encephalitis * anti-N-methyl-d-aspartate (NMDA) Receptor (350 patients), autoimmune disorder in which antibodies attack N-methyl-D-aspartate-type glutamate receptors * anti-gamma-aminobutyric acid-B (GABAb) receptor (35 patients), autoimmune disorder in which antibodies attack gamma-aminobutyric acid-B receptors * anti-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor (15 patients), autoimmune disorder in which antibodies attack alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors * without antibodies (50 patients).
Primary outcomes (1)
- measure
- Proportion of mutations in cancer genes coding for onconeural proteins and inflammatory response mediators.
- timeFrame
- 36 months
- description
- Genetic alterations in tumors associated with Paraneoplastic neurological syndromes (PNS)
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * presence of well characterized antibodies in serum or cerebrospinal fluid; * histologically proven cancer with available tumour sample; * Paraneoplastic neurological syndrome (PNS) diagnosis according to the international guidelines; * Age: at least 18 years old. Exclusion Criteria: * Absence of complete clinicopathological data
References
Publications (0)
Data not yet available